ENGLISH
|
JAPANESE
|
CONNECT WITH US:
Home
About
Contact
Log in
*
Home
Press release
2023年01月05日 12時50分
Source:
Eisai
エーザイ、2023年年頭所感
東京, 2023年01月05日 - (JCN Newswire) - エーザイ株式会社 代表執行役CEO・内藤晴夫は本日、2023年 年頭所感を述べました。
野のうさぎ飛びて天下の晴となる
米国でのレカネマブの迅速承認の可否のタイミングを控え、緊張感を持って迎えた年始となった。新たな治療薬を一日も早く届けてほしいという人々の期待に応えていかなければいけない。
昨年は、株主総会にて 17 年ぶりに定款を改定した。ヒューマン・ヘルスケア(hhc)理念のもと、「日本発のイノベーション企業として人々の健康憂慮の解消と医療較差の是正という社会善を効率的に実現する」ことを定款に加え、当社の社会課題解決に取り組む姿勢を改めて明確に定めた。現代社会において、企業が従来の「リスク」、「リターン」に加え、「インパクト」の評価軸を踏まえ、社会課題の解決に取り組むことが期待されており、当社の新たな定款は、その期待に合致するものである。
定款で定めた企業像の実現、価値の創造に向けてしっかりと持続的に取り組んでいくことが、当社の企業活動そのものである。
2023 年は、新定款のもと、気持ちを新たに当社のミッション実現に向けて全社一丸となって邁進していく。
2023年1月5日
エーザイ株式会社
代表執行役 CEO
内藤 晴夫
概要:エーザイ株式会社
詳細は www.eisai.co.jp をご覧ください。
Source: Eisai
セクター: バイオテック
Copyright ©2025 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.
Latest Release
"TOKIO Exciting Anime Workshop" Confirmed - Enjoy "Summer Festival at Anime Tokyo Station" This Summer Vacation
Jul 17, 2025 11:00 JST
International Land Alliance Unveils New Revenue Model Featuring 100 Rental Homes in Cabo Oasis
Jul 16, 2025 22:00 JST
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
Jul 16, 2025 14:50 JST
New Trains for Singapore's Sengkang-Punggol LRT Begin Commercial Operation
Jul 16, 2025 14:34 JST
AUG East Consortium and NEC to develop high-capacity submarine cable system across East Asia
Jul 16, 2025 14:00 JST
Anime Tokyo Station: Mobile Suit Gundam GQuuuuuuX -Beginning- Special Exhibition - New Designs Added for Admission Bonus Illustration Cards
Jul 16, 2025 11:00 JST
Fujitsu Data Intelligence PaaS enhances Mazda's data-utilization and decision-making
Jul 16, 2025 10:30 JST
Fujitsu and Acer Medical trial AI service that assesses future disease risk in elderly patients through gait pattern abnormality detection
Jul 16, 2025 10:20 JST
All Nippon Airways and Hitachi Unveil Japan's First Airline "Operations Brain" System, Enabling Rapid, Optimal Flight Schedule Revisions During Disruptions
Jul 15, 2025 12:00 JST
Fujitsu's AI-powered supply chain solution selected as transformative example of applied-AI technology by World Economic Forum
Jul 14, 2025 10:30 JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
Jul 14, 2025 10:20 JST
Mitsubishi Motors Added to FTSE4Good Index Series, FTSE Blossom Japan Index and FTSE Blossom Japan Sector Relative Index for Consecutive Years
Jul 11, 2025 16:28 JST
All-New MAZDA CX-5 Debuts in Europe
Jul 10, 2025 18:56 JST
Sharp Signs Official Partnership with Tottenham Hotspur FC Pre-season Tour 2025 with Its AQUOS Brand
Jul 10, 2025 17:30 JST
Hitachi develops "Metaverse Platform for Nuclear Power Plants" to enhance efficiency in construction and maintenance operations
Jul 09, 2025 19:02 JST
"Development of Integrated Simulation Platform for Sustainable and Competitive Maritime Industry" has been selected as a R&D project under K Program
Jul 08, 2025 20:30 JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
Jul 08, 2025 09:31 JST
MHI Awarded Contract for Basic Design of Japan's Largest CO2 Capture Plant at Hokkaido Electric Power's Tomato-Atsuma Power Station
Jul 07, 2025 11:15 JST
Fujitsu's high-precision skeleton recognition AI adopted to enhance figure skating athlete training
Jul 05, 2025 13:40 JST
DENSO Acquires Axia Vegetable Seeds to Realize Sustainable Agriculture
Jul 04, 2025 16:20 JST
More Latest Release >>
Related Release
Eisai Awarded "The 9th Bioindustry Award" for Drug Discovery Research for Anti- Amyloid B Monoclonal Antibody Lecanemab
7/16/2025 2:50:00 PM JST
"URECE" (Dotinurad) Launched in China as a treatment for Gout
7/14/2025 10:20:00 AM JST
Eisai Selected as Supplier Engagement Leader, CDP's Highest Rating in the Supplier Engagement Assessment
7/8/2025 9:31:00 AM JST
Eisai to Launch "Pariet S," the First Proton Pump Inhibitor RX-to-OTC in Japan
6/2/2025 5:46:00 PM JST
New Drug Approval for In-House Developed Anti-Insomnia Drug DAYVIGO (Lemborexant) in China
5/28/2025 5:45:00 PM JST
Eisai Demonstrates Commitment to Oncology Innovation at ASCO 2025
5/21/2025 3:00:00 PM JST
Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
5/16/2025 5:21:00 PM JST
Eisai Representative Corporate Officer and CEO Haruo Naito Awarded the Order of the Rising Sun, Gold and Silver Star
4/30/2025 2:17:00 PM JST
Leqembi (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer's Disease to be Authorized in the European Union
4/18/2025 4:52:00 PM JST
Eisai to Divest Rights for Pariet in China to Peak Pharma
4/1/2025 1:15:00 PM JST
More Press release >>